High Purity Pharmaceutical Grade Synthetic Drug Rivastigmine Tartrate CAS 129101-54-8

Rivastigmine tartrate is the tartrate salt of Alzheimer's disease treatment drug Rivastigmine, Rivastigmine is a physostigmine derivative, the trade name is exelon, and the molecule has a phenyl carbamate structure. A carbamate-like brain-selective cholinesterase inhibitor, which can inhibit both acetylcholinesterase and butyrylcholinesterase, and promote cholinergic nerve conduction by delaying the degradation of released acetylcholine by cholinergic neurons. Improve cholinergic-mediated cognitive dysfunction, thereby improving cognitive function in Alzheimer's disease patients. Rivastigmine has weak plasma protein binding, easily crosses the blood-brain barrier, and has a high degree of brain selectivity. It not only selectively acts on the most affected areas of the cerebral cortex and hippocampus, but also preferentially inhibits the dominant subtype of AChE in the brain, reducing peripheral cholinergic side effects while producing efficacy. Rivastigmine tartrate has a short half-life in the body and a long duration of action. Unlike tacrine, rivastigmine tartrate has a stronger inhibitory effect on G1 enzymes in the hippocampal and cortical regions. It is clinically used to treat mild to moderate Alzheimer's dementia, namely suspected Alzheimer's disease or Alzheimer's disease.